Chromaderm Overview

  • Founded
  • 2014
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $3.6M
Latest Deal Amount
  • Investors
  • 1

Chromaderm General Information


Developer of topical PKC-beta inhibitor intended to treat hyperpigmentation disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • One Mifflin Place
  • Suite 400
  • Cambridge, MA 02138
  • United States
+1 (617) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Chromaderm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 13-Oct-2015 $3.6M 00.00 000.00 Completed Startup
To view Chromaderm’s complete valuation and funding history, request access »

Chromaderm Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00 00 00 00 00.000
To view Chromaderm’s complete cap table history, request access »

Chromaderm Executive Team (2)

Name Title Board Seat Contact Info
James Fordyce Co-Founder, Chief Financial Officer & Board Member
Mark De Souza Ph.D Co-Founder, Chief Executive Officer, President & Board Member
To view Chromaderm’s complete executive team members history, request access »

Chromaderm Board Members (4)

Name Representing Role Since
Chun Chung Kwong Self Board Member 000 0000
James Fordyce Chromaderm Co-Founder, Chief Financial Officer & Board Member 000 0000
Karoly Nikolich Ph.D Self Board Member 000 0000
Terence Lam Ting Yin Self Board Member 000 0000
To view Chromaderm’s complete board members history, request access »

Chromaderm Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Nan Fung Life Sciences Venture Capital Minority 000 0000 000000 0
To view Chromaderm’s complete investors history, request access »